54 results about "Acidosis" patented technology

S-Beta-hydroxybutyric acid compositions for oral delivery are effective in rapidly raising blood ketone levels without causing acute acidosis or gastrointestinal (GI) distress when consumed in sufficiently dilute form and / or as a gel or suspension. By limiting added beta-hydroxybutyrate salts containing alkali or alkaline earth metal ions, beta-hydroxybutyric acid solutions, gels, or suspensions can deliver exogenous ketone bodies without significantly altering electrolyte balance. Although aqueous beta-hydroxybutyric acid solutions are moderately acidic with a pH of about 3.5 to 4, when diluted with sufficient water, the water acts as a pseudo buffering agent that offsets otherwise harsh acidic effects when consumed orally. Gels and suspensions can also ameliorate acidic effects by partially encapsulating the beta-hydroxybutyric acid. Beta-hydroxybutyric acid can be pure S-beta-hydroxybutyric acid or a non-racemic mixture enriched with S-beta-hydroxybutyric acid relative to R-beta-hydroxybutyric acid.

The invention provides a composition of a salvianolic acid extract and a tanshinone extract as well as a preparation method, application and a product of the composition, and belongs to the field of medicines. The preparation method of the composition of the salvianolic acid extract and the tanshinone extract comprises steps 1)-4). The composition with carbonic anhydrase inhibitory activity is obtained by extracting the salvianolic acid extract and the tanshinone extract from the radix salviae miltiorrhizae and mixing the salvianolic acid extract and the tanshinone extract, the composition can achieve synergistic interaction, and reference is provided for research and development and component compatibility of medicines mainly comprising the radix salviae miltiorrhizae. The composition provided by the invention can be used for reducing intraocular pressure, inducing diuresis, correcting metabolic acidosis, increasing vascular oxygen flux, improving pulmonary ventilatory capacity, expanding cerebral vessels, inducing tumor cell apoptosis and inhibiting osteoclast bone resorption; the traditional Chinese medicine composition can be used for treating or preventing diseases with intraocular hypertension as symptoms, cardiac edema or acute altitude sickness, cardiovascular and cerebrovascular diseases and bone metabolism diseases caused by osteoporosis.

The compositions comprise at least two ingredients selected from the group consisting of fish oil, L-arginine, vitamin E, vitamin C, vitamin B3, vitamin B5, vitamin B6, vitamin B1, vitamin B2, folic acid, biotin, vitamin B12, and are formulated for the prevention and / or treatment of a disease or condition associated with muscle decline in a subject in need thereof. Preferably, the subject in need is an individual at risk of or having renal failure, renal dysfunction or / and nephropathy, such as chronic nephropathy, protein energy consumption, end-stage nephropathy, renal failure due to hospitalization in an intensive care unit, acute kidney injury, and the muscle decline is selected from the group consisting of muscle depletion, muscle loss due to renal failure or dysfunction, muscle decline associated with chronic kidney disease, muscle loss due to hospitalization in intensive care units during renal failure, metabolic acidosis during chronic kidney disease, protein energy depletion, or a combination thereof. The method enables the prevention and / or treatment of at least one outcome of a disease or condition associated with muscle decline in a subject at risk of or having renal failure, renal dysfunction or / and kidney disease. The composition and the method can be used to improve the level of at least one amino acid.

S-Beta-hydroxybutyric acid compositions for oral delivery are effective in rapidly raising blood ketone levels without causing acute acidosis or gastrointestinal (GI) distress when consumed in sufficiently dilute form and / or as a gel or suspension. By limiting added beta-hydroxybutyrate salts containing alkali or alkaline earth metal ions, beta-hydroxybutyric acid solutions, gels, or suspensions can deliver exogenous ketone bodies without significantly altering electrolyte balance. Although aqueous beta-hydroxybutyric acid solutions are moderately acidic with a pH of about 3.5 to 4, when diluted with sufficient water, the water acts as a pseudo buffering agent that offsets otherwise harsh acidic effects when consumed orally. Gels and suspensions can also ameliorate acidic effects by partially encapsulating the beta-hydroxybutyric acid. Beta-hydroxybutyric acid can be pure S-beta-hydroxybutyric acid or a non-racemic mixture enriched with S-beta-hydroxybutyric acid relative to R-beta-hydroxybutyric acid.

The invention provides amperometric analyte sensor systems comprising one or more electrodes designed to monitor in vivo levels of 3-hydroxybutyrate (and optionally glucose as well) in order to facilitate the management of diabetic ketoacidosis. The invention further includes compositions, elements and methods useful with such amperometric analyte sensor systems.

The invention discloses a DKA combined AP risk prediction model based on multi-index fusion, a medium and equipment, and relates to the technical field of medical health and artificial intelligence, and the risk prediction model comprises a preprocessing unit which is used for carrying out the standardization processing of basic data and clinical data of a diabetic ketoacidosis patient, the clinical data comprises stomachache symptoms, C reactive protein level and serum lipase level; the screening unit is used for screening the basic data according to an exclusion mechanism; the data integration unit is used for obtaining the probability of occurrence of DKA and AP events by combining the following formula according to the screening result: Q = 1 / (1 + e-(beta0 + beta1 * stomachache + beta2 * CRP + beta3 * LPS)); and the output unit is used for outputting the probability calculated by the data integration unit as a result. Under the emergency treatment scene, the risk of acute pancreatitis complicated by the diabetic ketoacidosis patient can be rapidly evaluated, and a good preposed basis is provided for clinical decision making.

The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and / or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation, as well as retinal edema), as well as hyponatremia and excess fluid retention, and diseases such as epilepsy, retinal ischemia and other diseases of the eye associated with abnormalities in intraocular pressure and / or tissue hydration, myocardial ischemia, myocardial ischemia / reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines, as well as to novel assays for identifying aquaporin inhibitors.

Embodiments of the present invention include methods of targeting acidosis (low pH) within the tumor microenvironment (TME) through the use of cathodic electrochemical reactions (CER). Low pH is oncogenic by supporting immunosuppression. Electrochemical reactions create local pH effects when a current passes through an electrolytic substrate such as biological tissue. Electrolysis has been used with electroporation (destabilization of the lipid bilayer via an applied electric potential) to increase cell death areas. However, the regulated increase of pH through only the cathode electrode has been ignored as a possible method to alleviate TME acidosis, which could provide substantial immunotherapeutic benefits. Here, ex vivo modeling shows that CERs can intentionally elevate pH to an anti-tumor level and that increased alkalinity promotes activation of naïve macrophages. Embodiments of the invention include pairing CER treatment protocols with existing electric field-based cancer therapies or use as a stand-alone therapy.

The invention discloses a dynamic evaluation system which comprises a database and a deep learning model. The database is used for collecting multiple indexes of a user in real time, the deep learning model performs prediction based on the multiple indexes, and the real-time recommended dosage of sodium bicarbonate used by the user is predicted; the database comprises an acquisition baseline index, an information index and an end index; the deep learning model comprises a preprocessing unit, an XGBOOST calculation unit, an SHAP analysis unit, a regression prediction sub-model and an output unit. Based on the indexes of various physiological parameters of the user, especially the important function of the chloride ion level in metabolic acidosis analysis, accurate prediction is performed in the deep learning model, so that the real-time recommended dosage of sodium bicarbonate is accurately output, and the curative effect is effectively improved.

The invention relates to the technical field of feed additives, in particular to a sustained-release composition for solving ruminant rumen acidosis as well as a preparation method and application of the sustained-release composition. The composition is prepared from the following components in parts by weight: 30 to 60 parts of complex microbial inoculant capsules, 10 to 30 parts of thiamine, 5 to 15 parts of light calcium carbonate, 5 to 15 parts of magnesium oxide, 8 to 18 parts of sodium bicarbonate, 2 to 5 parts of rare earth elements, 3 to 8 parts of rhizoma coptidis, 5 to 15 parts of rhizoma atractylodis macrocephalae, 4 to 9 parts of poria cocos and 2 to 5 parts of rhizoma corydalis. The complex microbial inoculant capsule at least comprises parabacteroides dieldrii, bacillus subtilis, bacillus licheniformis, enterococcus faecalis and lactobacillus rosenbergii; the rare earth element is a mixture of lanthanum nitrate and cerous nitrate, and the mass ratio of lanthanum nitrate to cerous nitrate is 1: 1. The composition can be used for preventing and treating ruminant rumen acidosis, can be slowly released in the stomach due to the slow release effect, and does not need to be used as a feed additive all the time.

The invention provides a ruminant rumen health monitoring and conditioning integrated device and an acidosis prevention method, and relates to the technical field of rumen monitoring, the ruminant rumen health monitoring and conditioning integrated device comprises a fixed seat, a fixed cylinder is fixed at the bottom of the fixed seat, an elastic plate is fixed at the bottom of the fixed cylinder, and a movable cylinder is fixed at one end of the bottom of the elastic plate; and a limiting plate is movably mounted on the side of the fixed seat. A rotating seat rotates on a rotating ring, the rotating seat drives a threaded column to move upwards when rotating, the threaded column moves upwards through a positioning pipe and a positioning column, the positioning column moves upwards to drive a supporting disc to move, and the supporting disc moves to push a supporting rod to open towards the side; after the supporting rod is unfolded, the elastic plate circularly expands to form a supporting point from the interior of the animal, the elastic plate is matched with the fixed seat to achieve extrusion sealing installation under different thicknesses, and the movable barrel drives the initial height of the monitoring assembly to be adjusted under the movement of the elastic plate.

The present disclosure provides, inter alia, pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. In certain embodiments, the pharmaceutical compositions contain nonabsorbable pharmaceutical composition and may be used, for example, to treat eubicarbonatemic metabolic acidosis.

A method including administering a therapeutically effective amount of a therapeutic agent to a subject for improving exercise performance, treating obesity, fatty liver, rhabdomyolysis, Leigh syndrome, mitochondrial Complex I deficiency, fatty acid oxidation disorders, lactic acidosis, metformin toxicity, ischemic acute kidney injury, or nephrotoxin-induced kidney injury, wherein the therapeutic agent is a straight-chain saturated dicarboxylic acid of 8 to 12 carbons in length, a triglyceride made from a straight-chain saturated dicarboxylic acid of 8 to 12 carbons in length, a metabolic intermediate produced during the catabolic chain-shortening of a straight-chain dicarboxylic acid of 8 to 12 carbons in length, a salt thereof, or a mixture thereof.

The invention provides a traditional Chinese medicine composition for preventing and treating cattle hoof diseases as well as a preparation method and application thereof, and belongs to the technical field of veterinary traditional Chinese medicines. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 30 to 40 parts of honeysuckle flower, 15 to 20 parts of herba artemisiae scopariae, 20 to 25 parts of radix astragali seu hedysari, 12 to 18 parts of poria cocos, 10 to 15 parts of rhizoma atractylodis macrocephalae, 6 to 12 parts of radix angelicae sinensis, 4 to 8 parts of radix paeoniae rubra, 12 to 18 parts of rhizoma dioscoreae, 9 to 13 parts of fructus cnidii, 8 to 12 parts of radix achyranthis bidentatae and 5 to 10 parts of liquorice root. The traditional Chinese medicine composition is scientific in formula, has the effects of clearing away heat and toxic materials, eliminating dampness and astringing sores, tonifying qi and activating blood, relieving swelling and pain and strengthening tendons and bones through combination of the medicines, can effectively prevent and treat common hoof diseases such as foot rot, cattle laminitis and hoof abscess caused by factors such as acidosis, bacterial infection and downward flow of damp-heat, and has the advantages of remarkable curative effect, no medicine residue, high safety and the like.

The invention provides amperometric analyte sensor systems comprising one or more electrodes designed to monitor in vivo levels of 3-hydroxybutyrate (and optionally glucose as well) in order to facilitate the management of diabetic ketoacidosis. The invention further includes dual layer membrane compositions, elements and methods useful with such amperometric analyte sensor systems.

A traditional Chinese medicine compound for nourishing yin, clearing heat and removing blood stasis for treating primary Sjögren's syndrome combined with renal tubular acidosis and its preparation method, belonging to the field of traditional Chinese medicine compound preparations. The traditional Chinese medicine compound for nourishing yin, clearing heat and removing blood stasis is composed of Achyranthes bidentata, Rhizoma Alismatis, Radix Rehmanniae, Radix Angelicae Sinensis, Fructus Cuscutae, Fructus Rosae Laevigatae, Fructus Cuscutae, Rhizoma Gentianae, Rhizoma Phragmites, Cortex Moutan, Solanum nigrum, Astragalus, Plantago, Dendrobium, Atractylodes, Fructus Corni, Leonurus japonicus, and Licorice. This disease is a syndrome of deficiency in the root and excess in the superficial, or a mixture of deficiency and excess, with kidney yin deficiency as the root and damp-heat and blood stasis as the superficial, the two being mutually causal. Kidney yin deficiency leads to the internal generation of virtual fire, burning body fluid and causing dryness. In addition, due to the internal heat of yin deficiency, the body fluid is refined into phlegm, which accumulates in the three energizers, obstructing the qi flow, generating internal damp heat. The damp heat is long-term trapped in the kidney meridians, causing qi stagnation and blood stasis, forming a state of "dampness, heat, and blood stasis" obstruction, ultimately presenting a syndrome of deficiency in the root and excess in the superficial, or a mixture of deficiency and excess. Therefore, the present invention combines these drugs to produce a synergistic effect on the efficacy of each drug, thereby achieving the effects of nourishing yin and tonifying the kidney, clearing away heat and dampness, and promoting blood circulation and removing blood stasis.

The present invention may be directed to compositions and methods for the treatment of alopecia / epilation, which may include the treatment of alopecia conditions. Compositions and methods relate to oral supplements of oral minoxidil, including an SLC22A9 inducer, an HIF-alpha inducer, and / or an acidulant. Acidification of blood in patients with alopecia may cause mild acidosis, which may up-regulate SLC22A9 and / or down-regulate AABC3. Inducing SLC22A9, inducing HIF-alpha, and / or acidifying the patient's blood can promote oral form of minoxidil into hair follicles.

The invention belongs to the field of animal nutrition and feed science, and relates to a feeding technology capable of improving production performance, body health (immunity and oxidation resistance) and economic benefit of mutton sheep and improving rumen pH value, blood buffer capability and blood acid-base balance maintaining capability, namely preventing chronic rumen acidosis, and a daily ration preparation method thereof. According to the feeding technology and the daily ration preparation method, vitamin B12 (cyanocobalamine) is added into the mutton sheep high-concentrate daily ration (the concentrate-to-coarse ratio is 6: 4), the adding level is 0.5 mg / kg in terms of dry matter per kg of the daily ration, it is at least guaranteed that the pre-feeding period is 7 days and the positive test period is 30 days or above in the feeding time of the mutton sheep, the production performance, the organism immunity, the oxidation resistance and the economic benefits of the mutton sheep can be improved, and the mutton sheep feed is suitable for large-scale production. The pH value of the rumen, the blood buffering power and the blood acid-base balance maintaining capacity are improved, namely the effect of preventing chronic acidosis of the rumen is achieved, and the mutton sheep feed additive is suitable for mutton sheep with the weight being 34 kg or above. The method is easy to operate and safe in production, and a new thought and method are provided for preventing chronic rumen acidosis under the condition that mutton sheep are fed with high-concentrate daily ration.

The invention relates to the technical field of medical apparatus and instruments, in particular to an anesthesia monitoring system for connection of tumor cell debilitation and intraperitoneal hyperthermic perfusion chemotherapy. The system comprises: a cardiopulmonary monitoring module configured to collect cardiopulmonary key indexes of a to-be-monitored object in real time from a tumor cell deficit anesthesia guide period; the body temperature monitoring module is configured to monitor the body temperature of a to-be-monitored object in real time and obtain a body temperature change baseline value; the acidosis intervention confirmation module is configured to preventively generate acidosis intervention information corresponding to the to-be-monitored object; the control module is configured to process the cardiopulmonary key indexes, the body temperature change data and the acidosis intervention state based on a preset algorithm to generate an anesthesia depth adjusting signal, the preset algorithm is configured to enable the cardiopulmonary key indexes, the body temperature change data, the acidosis intervention state and the mechanical retardation effect to form a correlation calculation model which decreases progressively; and adjusting the anesthesia depth in real time based on the anesthesia depth adjusting signal.

The invention discloses a treatment guidance system for a diabetic ketoacidosis patient. According to the system, a data detection unit is used for acquiring symptom related data of a target patient; the decision analysis unit is used for generating a corresponding first treatment scheme based on the symptom related data in combination with a stored treatment guide; the scheme recommendation unit is used for generating a second treatment scheme based on the first treatment scheme in response to an auditing result of the auditing terminal on the first treatment scheme, and then sending the second treatment scheme to the execution terminal; and the infusion monitoring unit is used for responding to the instruction of the execution end, automatically controlling infusion treatment on the target patient based on the second treatment scheme and automatically adjusting the dosage in combination with the detection index. According to the invention, the treatment success rate of DKA patients is effectively improved, and the incidence rate of adverse events such as hypoglycemia and prolonged uridone body negative conversion time is reduced.

This invention belongs to the field of biochemistry, and specifically relates to a β-hydroxybutyrylation modification biomarker of OXCT1 and its application in the diagnosis and treatment of ketoacidosis. A biomarker for ketoacidosis is a β-hydroxybutyrylation modification of lysine 421 on the OXCT1 protein. This biomarker is used in the diagnosis of ketoacidosis by detecting the Kbhb modification level of OXCT1 and the expression level of OXCT1 in various ketone body utilizing organs, serving as an auxiliary diagnostic indicator for ketoacidosis. In the treatment of ketoacidosis, the Kbhb modification of lysine 421 on the OXCT1 protein is used as a therapeutic target for patients with ketoacidosis, and can be applied to the treatment of ketoacidosis to reduce blood ketone levels. This invention proposes a new diagnostic and treatment method for ketoacidosis. The biomarker can also be used to prepare diagnostic reagents or kits for ketoacidosis.

The present disclosure provides methods for treating, preventing, ameliorates, inhibits, or delaying the onset of Leigh syndrome as well as methods for ameliorating, inhibiting, ameliorates, inhibits, or delaying the onset of its associated signs and / or symptoms, such as exercise-induced acid acidosis, and increases in plasma levels of growth factor 15 (GDF-15) and / or fibroblast growth factor (FGF-21) in a subject in need thereof comprising administering to the subject various compounds, mixtures of compounds or compositions, formulations or medicaments derived therefrom.

The present application relates to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for treating transmissible gastroenteritis (TGE) of lactating piglets, which effectively solves the problem that the prior art is only directed to the transmissible gastroenteritis with a low mortality rate of the piglets or sows with a mild disease, is not directed to the TGE with a high mortality rate of the lactating piglets with a severe disease, and cannot rapidly correct the problems of dehydration and acidosis of the lactating piglets, compared with the prior art, the traditional Chinese medicine composition for treating the TGE of the lactating piglets comprises Nansha-Shen, Beisha-Shen, Shihu, Yuzhu, Oyster, and can nourish Yin and produce body fluid, can effectively improve the dehydration and metabolic acidosis of the lactating piglets, and achieve the effects of treating the TGE and reducing the mortality rate, and the reasonable process is adopted to prepare the traditional Chinese medicine composition, so that the traditional Chinese medicine composition is convenient to use.

Embodiments can relate to compositions and methods for the treatment of hair loss, which can include treatment of alopecia. The compositions and methods relate to an oral supplement to oral minoxidil includes a SLC22A9 inducer, a HIF-alpha inducer, and / or an acidifying agent. Acidifying blood of a patient suffering from alopecia can cause mild acidosis which can up-regulate SLC22A9 and / or down-regulate AABC3. Inducing SLC22A9, inducing HIF-alpha, and / or acidifying blood of the patient can facilitate oral forms of minoxidil to enter hair follicles.

The present invention relates to an orally administrable pharmaceutical dosage form configured to target delivery to the distal portion of the gastrointestinal tract of a human subject, the pharmaceutical dosage form comprising lanthanum or a pharmaceutically acceptable salt or oxide thereof. The present invention further relates to a pharmaceutical dosage form used in the treatment of hyperoxaluria in a human subject, optionally wherein the hyperoxaluria is primary hyperoxaluria or secondary hyperoxaluria; and / or a pharmaceutical dosage form used in the treatment of one or more of nephrolithiasis, nephrocalcinosis or oxalosis in a human subject.

The invention relates to the technical field of biological medicine, in particular to application of tripterine or medicinal salt thereof in preparation of medicine for treating ketoacidosis or symptoms caused by ketoacidosis. The invention provides application of tripterine or medicinal salt thereof in preparation of a medicine for treating ketoacidosis or symptoms caused by ketoacidosis. The result of the specific embodiment of the invention shows that the tripterine can obviously reduce the mouse serum beta-hydroxybutyric acid level caused by hunger; the tripterine can be used for remarkably reducing the expression of HMGCS2 in the liver of a mouse; the dapagliflozin remarkably promotes the level of beta-hydroxybutyric acid, and the tripterine remarkably reduces the level of mouse serum beta-hydroxybutyric acid caused by treatment of the dapagliflozin. Therefore, tripterine can be used for treating or improving ketoacidosis or symptoms caused by ketoacidosis. The invention provides a new technical scheme for treatment and improvement of ketoacidosis or symptoms caused by ketoacidosis.

A system includes an analyte measurement system and a software application operatively coupled to the analyte measurement system. The analyte measurement system is configured to measure an analyte of a patient. The software application is configured to retrieve sensor data of the analyte level, analyte rate of change, or both; detect at least one condition associated with the sensor data; and provide a notification to the patient associated with the at least one detected condition. Advantageously the system can detect current or impending adverse conditions (such as an insulin deficiency), provide custom notifications (e.g., warnings, recommendations, guidance) to the patient to act, prompt the patient for additional information relevant to the detected condition, continuously monitor glucose and ketone levels in real-time, control insulin delivery based on ketone level, and mitigate the risk of euglycemic diabetic ketoacidosis (euDKA).

The invention provides a composition for preventing or treating acidic urinary stone of pets and application of the composition. The composition comprises citrate, N-acetylglucosamine, a corn stigma extract and a lysimachia christinae hance extract. The citrate can compete with oxalate ions and is preferentially combined with calcium ions to form a soluble calcium citrate compound, so that formation and growth of calcium oxalate crystals are inhibited, and kidney metabolic acidosis caused by improper acidification of urine is prevented. N-acetylglucosamine can repair a glycosaminoglycan layer of a bladder mucosa, reduce crystal adhesion and urethra stimulation, inhibit bacteria from adhering to the urethra, and reduce calculus and infection risks; the corn stigma extract is used for diluting the oxalic acid concentration of urine by increasing the urine volume of pets; the active ingredients of the lysimachia christinae hance extract can relieve urinary tract inflammation and smooth muscle spasm and relieve pain. The composition provided by the invention can effectively reduce formation of acidic urinary stones of pets, prevent bacterial adhesion and recurrent cystitis, and improve urinary system health of pets.

The invention belongs to the technical field of biochemistry, and particularly relates to a beta-hydroxybutyrylation modification marker of OXCT1 and application of the beta-hydroxybutyrylation modification marker in diagnosis and treatment of ketoacidosis. The invention relates to a marker for ketoacidosis. The marker is modified by beta-hydroxybutyrylation on lysine at the 421st site of OXCT1 protein. The marker is applied to diagnosis of ketoacidosis, and by detecting the Kbhb modification level of OXCT1, the expression quantity of OXCT1 of each ketone body utilization organ is detected and serves as an index for auxiliary diagnosis of ketoacidosis. According to the application of the marker in treatment of ketoacidosis, Kbhb modification of lysine at the 421st site of OXCT1 protein serves as a treatment target of a ketoacidosis patient, and the marker can be applied to treatment of ketoacidosis so as to reduce the blood ketone level. The invention provides a novel diagnosis and treatment method for ketoacidosis. The marker can also be applied to preparation of a ketoacidosis diagnosis reagent or kit.

An ultrasound image 2010 of part of a foetus is obtained, and the foetus is assessed by automated analysis of the image using a deep learning model 2020 of an artificial intelligence unit. In an aspec